Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): Need for a high daily dose of 800 mg

Nephrology Dialysis Transplantation

Volumn 21, Issue 4, 2006, Pages 1019-1023

  Bergner, Raoul ^a   Hoffmann, Martin ^a   Riedel, Klaus Dieter ^b   Mikus, Gerd ^b   Henrich, Dirk M ^a   Haefeli, Walter E ^b   Uppenkamp, Michael ^a   Walter Sack, Ingeborg ^b  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Candida septicemia; CVVHF; Fluconazole dosing; Fluconazole levels; Haemofiltration; Ultrafiltration rates

Indexed keywords

FLUCONAZOLE;

AREA UNDER THE CURVE; ARTICLE; CANDIDA GLABRATA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS HEMODIAFILTRATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; CROSSOVER PROCEDURE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG SENSITIVITY; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; KIDNEY FAILURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; SINGLE BLIND PROCEDURE; ULTRAFILTRATION;

ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; CROSS-SECTIONAL STUDIES; FLUCONAZOLE; HEMOFILTRATION; HUMANS; KIDNEY FAILURE, ACUTE; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 33645316477     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi284     Document Type: Article

References (18)

1. Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993; 12: 10-27
2. Berl T, Wilner KD, Gardner M et al. Pharmacokinetics of fluconazole in renal failure. J Am Soc Nephrol 1995; 6: 242-247
3. Böhler J, Donauer J, Keller F. Pharmacokinetic principles during continuous renal replacement therapy: Drugs and dosage. Kidney Int 1999; 56 [Suppl]: 24-28
4. Toon S, Ross CE, Gokal R, Rowland M. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol 1990; 29: 221-226
5. Oono S, Tabei K, Tetsuka T, Asano Y. The pharmacokinetics of fluconazole during haemodialysis in uremic patients. Eur J Clin Pharmacol 1992; 42: 667-670
6. Nicolau DP, Crowe H, Nightingale CH, Quintiliani R. Effect of continuous arteriovenous hemodiafiltration on the pharmacokinetics of fluconazole. Pharmcotherapy 1994; 14: 502-505
7. Scholz J, Schulz M, Steinfath M, Höver S, Bause H. Fluconazole is removed by continuous venovenous hemofiltration in a liver transplant patient. J Mol Med 1995; 73: 145-147
8. Schetz M, Ferdinande P, Van den Berghe G, Verwaest C, Lauwers P. Pharmacokinetics on continuous renal replacement therapy. Intensive Care Med 1995; 21: 612-620
9. Pfaller MA, Messer SA, Boyken L, Huynh H, Hollis RJ, Diekema DJ. In vitro activities of 5-fluorocytosine against 6,970 clinical isolates of Candida spp.: Global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob Agents Chemother 2002; 46: 3518-3521
10. Pittrow L, Penk A. Plasma and tissue concentration of fluconazole and their correlation to breakpoints. Mycoses 1996; 39 [Suppl]: 1-8
11. Wolter K, Marggraf G, Dermoumi H, Fritschka E. Elimination of fluconazole during continuous veno-venous haemodialysis (CVVHD) in a single patient. Eur J Clin Pharmacol 1994; 47: 291-292
12. Valtonen M, Tiula E, Neuvonen PJ. Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure. J Antimicrob Chemother 1997; 40: 695-700
13. Pittrow L, Penk A, Pharmacokinetics and dosage of fluconazole in continuous haemofiltration (CAVH, CVVH) and haemodialysis (CAVHD, CVVH). Mycoses 1998; 41 [Suppl]: 86-88
14. Muhl E, Martens T, Iven H, Rob P, Bruch HP. Influence of continuous veno-venous haemodiafiltration and continuous haemofiltration on pharmacokinetics of fluconazole. Eur J Clin Pharmacol 2000; 56: 671-678
15. Yagasaki K, Gando S, Matsuda N et al. Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. Intensive Care Med 2003; 29: 1844-1848
16. Reetze-Bonorden P, Böhler J, Keller E. Drug dosage in patients during continuous renal replacement therapy - pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993; 24: 362-379
17. Anaissie EJ, Kontoyiannis DP, Huls C et al. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995; 172: 599-602
18. Pfaller MA, Diekema DJ. Twelve years of fluconazole in clinical practice: Global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol Infect 2004; 10 [Suppl 1]: 11-23